Abstract
Introduction:
We conducted a feasibility study on docetaxel/capecitabine/cisplatin (DCX) with chemoradiotherapy as adjuvant treatment for gastric cancer patients.
Methods:
Patients were scheduled to receive 2 cycles of DCX, followed by 50.4 Gy plus capecitabine as radiotherapy, followed by an additional 2-DCX cycles.
Results:
From the 40 enrolled patients, 26 (65%) completed treatment as per protocol and 14 (35%) discontinued with the treatment (patients' refusal: n=6; adverse events: n=8). There were 2 toxic deaths. Grade >3 toxicity was 12.1% before and 13.3% after chemoradiotherapy. Disease progression was documented in 11 (27.5%) patients.
Conclusions:
No further development of this regimen is justified on the basis of poor tolerability in patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / therapy*
-
Adult
-
Aged
-
Anemia / chemically induced
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine
-
Chemoradiotherapy, Adjuvant / methods
-
Cisplatin / administration & dosage
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Docetaxel
-
Feasibility Studies
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Gastrectomy*
-
Heart Arrest / chemically induced
-
Humans
-
Leukopenia / chemically induced
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Sepsis / etiology
-
Stomach Neoplasms / therapy*
-
Taxoids / administration & dosage
-
Treatment Outcome
Substances
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Capecitabine
-
Cisplatin
-
Fluorouracil